VFA
VIRX

Virtus Fund Advisers’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Virtus Fund Advisers’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-20
Closed -$28K – 2005
2014
Q2 		$28K Buy
+20
New +$23.2K ﹤0.01% 2250

Other funds holding VIRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCP
Lamond Capital Partners San Francisco, California $14.3M AUM 30.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Virtus Fund Advisers's VIRX Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2014, closing a stake of 20 shares — an estimated $28K sold.

Virtus Fund Advisers first reported a position in VIRX in Q2 2014 and held it in 1 quarter. The position peaked at $28K in Q2 2014. 104 funds tracked by Wall St. Rank hold VIRX as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 20 Viracta Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $28K.
  • Virtus Fund Advisers first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Viracta Therapeutics, Inc. Common Stock position peaked at $28K in Q2 2014.
  • 104 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.